Literature DB >> 29735568

A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.

Patricia A Bradford1, Michael D Huband1, Gregory G Stone2.   

Abstract

Selection of the avibactam concentration to combine with ceftazidime in susceptibility testing was determined using Gram-negative isolates with characterized β-lactamases predefined as susceptible or resistant, based on the known inhibition spectrum of avibactam. MIC values were determined by broth microdilution of ceftazidime with fixed concentrations and ratios of avibactam. A constant concentration of 4 μg/ml of avibactam was selected for susceptibility testing with ceftazidime because of its ability to correctly categorize susceptible and resistant isolates while minimizing categorical errors.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  MIC testing; beta-lactamase inhibitor combination; ceftazidime-avibactam

Mesh:

Substances:

Year:  2018        PMID: 29735568      PMCID: PMC6021650          DOI: 10.1128/AAC.00223-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  A comparison of agar dilution, identification of beta-lactamases and disc diffusion methods for assessing the sensitivity to ticarcillin-clavulanic acid.

Authors:  B Joly; M Chanal; D Sirot; M Cluzel; J Sirot; R Cluzel
Journal:  J Antimicrob Chemother       Date:  1986-05       Impact factor: 5.790

2.  Use of a predictor panel to evaluate susceptibility test methods proposed for piperacillin-tazobactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

3.  Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.

Authors:  P R S Lagacé-Wiens; F Tailor; P Simner; M DeCorby; J A Karlowsky; A Walkty; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

4.  Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.

Authors:  P G Ambrose; S M Bhavnani; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

5.  Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).

Authors:  R N Jones; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Nov-Dec       Impact factor: 2.803

6.  Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.

Authors:  David E Ehmann; Haris Jahić; Philip L Ross; Rong-Fang Gu; Jun Hu; Gunther Kern; Grant K Walkup; Stewart L Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

7.  In vitro evaluations of aminopenicillin/beta-lactamase inhibitor combinations.

Authors:  R N Jones
Journal:  Drugs       Date:  1988       Impact factor: 9.546

8.  Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.

Authors:  Dana Maglio; Christine Ong; Mary Anne Banevicius; Qiuming Geng; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

9.  Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection.

Authors:  Johanna Berkhout; Maria J Melchers; Anita C van Mil; Seyedmojtaba Seyedmousavi; Claudia M Lagarde; Virna J Schuck; Wright W Nichols; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

10.  Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia.

Authors:  Anouk E Muller; Nieko Punt; Johan W Mouton
Journal:  J Antimicrob Chemother       Date:  2012-11-28       Impact factor: 5.790

View more
  6 in total

1.  In Vitro Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial.

Authors:  Gregory G Stone; Patricia A Bradford; Margaret Tawadrous; Dianna Taylor; Mary Jane Cadatal; Zhangjing Chen; Joseph W Chow
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

2.  Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa.

Authors:  Wright W Nichols; Gregory G Stone; Paul Newell; Helen Broadhurst; Angela Wardman; Merran MacPherson; Katrina Yates; Todd Riccobene; Ian A Critchley; Shampa Das
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

3.  In Vitro Evaluation of Antifungal Drug Combinations against Multidrug-Resistant Candida auris Isolates from New York Outbreak.

Authors:  Brittany O'Brien; Sudha Chaturvedi; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

4.  Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide.

Authors:  Helio S Sader; Leonard R Duncan; S J Ryan Arends; Cecilia G Carvalhaes; Mariana Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 5.  The Ins and Outs of Susceptibility Testing for New β-Lactam/β-Lactamase Inhibitor Combinations for Gram-Negative Organisms.

Authors:  Tanis C Dingle; Johann Pitout
Journal:  J Clin Microbiol       Date:  2022-04-07       Impact factor: 11.677

6.  Sigmoid Emax Modeling To Define the Fixed Concentration of Enmetazobactam for MIC Testing in Combination with Cefepime.

Authors:  Philipp Knechtle; Stuart Shapiro; Ian Morrissey; Cyntia De Piano; Adam Belley
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.